136 related articles for article (PubMed ID: 32590026)
21. Deguelin, a selective silencer of the NPM1 mutant, potentiates apoptosis and induces differentiation in AML cells carrying the NPM1 mutation.
Yi S; Wen L; He J; Wang Y; Zhao F; Zhao J; Zhao Z; Cui G; Chen Y
Ann Hematol; 2015 Feb; 94(2):201-10. PubMed ID: 25242579
[TBL] [Abstract][Full Text] [Related]
22. Paradoxical effects of Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates on hCD45(+) cells in the bone marrow and spleen of leukemia-engrafted NOD/SCID or NRG mice.
Bergstrom D; Leyton JV; Zereshkian A; Chan C; Cai Z; Reilly RM
Nucl Med Biol; 2016 Oct; 43(10):635-41. PubMed ID: 27497632
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemia.
Zhou J; Bi C; Ching YQ; Chooi JY; Lu X; Quah JY; Toh SH; Chan ZL; Tan TZ; Chong PS; Chng WJ
J Hematol Oncol; 2017 Jul; 10(1):138. PubMed ID: 28693523
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia.
Folkerts H; Hilgendorf S; Wierenga ATJ; Jaques J; Mulder AB; Coffer PJ; Schuringa JJ; Vellenga E
Cell Death Dis; 2017 Jul; 8(7):e2927. PubMed ID: 28703806
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
[TBL] [Abstract][Full Text] [Related]
26. Mechanism of cytosine arabinoside toxicity to the blast cells of acute myeloblastic leukemia: involvement of free radicals.
Hu ZB; Yang GS; Li M; Miyamoto N; Minden MD; McCulloch EA
Leukemia; 1995 May; 9(5):789-98. PubMed ID: 7769841
[TBL] [Abstract][Full Text] [Related]
27. Kit inhibitor APcK110 extends survival in an AML xenograft mouse model.
Faderl S; Bueso-Ramos C; Liu Z; Pal A; Bornmann W; Ciurea DV; Harris D; Hazan-Halevy I; Kantarjian HM; Estrov Z
Invest New Drugs; 2011 Oct; 29(5):1094-7. PubMed ID: 20517635
[TBL] [Abstract][Full Text] [Related]
28. DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia.
Haines E; Nishida Y; Carr MI; Montoya RH; Ostermann LB; Zhang W; Zenke FT; Blaukat A; Andreeff M; Vassilev LT
Sci Rep; 2021 Jun; 11(1):12148. PubMed ID: 34108527
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
[TBL] [Abstract][Full Text] [Related]
30. Targeting the MTF2-MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy.
Maganti HB; Jrade H; Cafariello C; Manias Rothberg JL; Porter CJ; Yockell-Lelièvre J; Battaion HL; Khan ST; Howard JP; Li Y; Grzybowski AT; Sabri E; Ruthenburg AJ; Dilworth FJ; Perkins TJ; Sabloff M; Ito CY; Stanford WL
Cancer Discov; 2018 Nov; 8(11):1376-1389. PubMed ID: 30115703
[TBL] [Abstract][Full Text] [Related]
31. Inactivation of the p53-KLF4-CEBPA Axis in Acute Myeloid Leukemia.
Seipel K; Marques MT; Bozzini MA; Meinken C; Mueller BU; Pabst T
Clin Cancer Res; 2016 Feb; 22(3):746-56. PubMed ID: 26408402
[TBL] [Abstract][Full Text] [Related]
32. Effects of HOXA9 Inhibitor DB818 on the Growth of Acute Myeloid Leukaemia Cells.
Sonoda Y; Itoh M; Tohda S
Anticancer Res; 2021 Apr; 41(4):1841-1847. PubMed ID: 33813389
[TBL] [Abstract][Full Text] [Related]
33. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.
Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE
Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934
[TBL] [Abstract][Full Text] [Related]
34. Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway.
Eisfeld AK; Schwind S; Patel R; Huang X; Santhanam R; Walker CJ; Markowitz J; Hoag KW; Jarvinen TM; Leffel B; Perrotti D; Carson WE; Marcucci G; Bloomfield CD; de la Chapelle A
Sci Signal; 2014 Apr; 7(321):ra36. PubMed ID: 24736457
[TBL] [Abstract][Full Text] [Related]
35. The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cells.
Ruvolo PP; Ruvolo VR; Jacamo R; Burks JK; Zeng Z; Duvvuri SR; Zhou L; Qiu Y; Coombes KR; Zhang N; Yoo SY; Pan R; Hail N; Konopleva M; Calin G; Kornblau SM; Andreeff M
Biochim Biophys Acta; 2014 Sep; 1843(9):1969-77. PubMed ID: 24858343
[TBL] [Abstract][Full Text] [Related]
36. MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+ / CD131- epitope expressed by leukemia stem cells.
Leyton JV; Williams B; Gao C; Keating A; Minden M; Reilly RM
Leuk Res; 2014 Nov; 38(11):1367-73. PubMed ID: 25278187
[TBL] [Abstract][Full Text] [Related]
37. LGALS3 is connected to CD74 in a previously unknown protein network that is associated with poor survival in patients with AML.
Ruvolo PP; Hu CW; Qiu Y; Ruvolo VR; Go RL; Hubner SE; Coombes KR; Andreeff M; Qutub AA; Kornblau SM
EBioMedicine; 2019 Jun; 44():126-137. PubMed ID: 31105032
[TBL] [Abstract][Full Text] [Related]
38. Transcription factor AP-2α regulates acute myeloid leukemia cell proliferation by influencing Hoxa gene expression.
Ding X; Yang Z; Zhou F; Wang F; Li X; Chen C; Li X; Hu X; Xiang S; Zhang J
Int J Biochem Cell Biol; 2013 Aug; 45(8):1647-56. PubMed ID: 23660297
[TBL] [Abstract][Full Text] [Related]
39. RALB provides critical survival signals downstream of Ras in acute myeloid leukemia.
Eckfeldt CE; Pomeroy EJ; Lee RD; Hazen KS; Lee LA; Moriarity BS; Largaespada DA
Oncotarget; 2016 Oct; 7(40):65147-65156. PubMed ID: 27556501
[TBL] [Abstract][Full Text] [Related]
40. The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.
Nechiporuk T; Kurtz SE; Nikolova O; Liu T; Jones CL; D'Alessandro A; Culp-Hill R; d'Almeida A; Joshi SK; Rosenberg M; Tognon CE; Danilov AV; Druker BJ; Chang BH; McWeeney SK; Tyner JW
Cancer Discov; 2019 Jul; 9(7):910-925. PubMed ID: 31048320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]